UNDAUNTED

so Michele, who is living with PNH, can spend more time riding her beloved horse

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

We are a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.

Learn More
Folded page of a newspaper

Latest news

March 17, 2021

Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

March 10, 2021

Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy

March 4, 2021

Apellis Provides Update on APL-9 for Severe COVID-19

Newsroom
A man with a baby in a baby carrier

At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive.

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

We are advancing therapies

for PNH, geographic atrophy, ALS, C3G / IC-MPGN, and CAD.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

Our lead investigational products

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

we replace impossible with How

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
Female Apellis employee holding a pug

Patricia
Quality Assurance at Apellis